Trial Profile
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Esketamine (Primary)
- Indications Tinnitus
- Focus Adverse reactions; Registrational
- Acronyms AMPACT1
- Sponsors Altamira Therapeutics; Auris Medical
- 09 May 2017 According to an Auris Medical media release, this is the second of two open-label extension studies with Keyzilen that were conducted in response to a request from the US Food and Drug Administration (FDA) for safety data from chronic intermittent use of Keyzilen for up to 12 months.
- 09 May 2017 Results published in an Auris Medical Media Release
- 24 Apr 2017 According to an Auris Medical media release, results from this trial are expected later this quarter.